FDA Approves Updated Labeling For Psoriasis Drug Raptiva - Safety Concerns Drove Labeling Changes

The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA’s post-market surveillance.

More: continued here

Filed under: Dermatology on October 27th, 2008